Payment overview · 2025
General Payments
$149,351.88
229 reported records · 15 companies
Healthcare provider profile · identity verified
Mario Vukic, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HACKENSACK, NJ · NPI 1043287865
Verified facts
What the public records show
CMS Open Payments records show Mario Vukic, MD received $149,351.88 in general payments during 2025 across 229 reported records.
ARGENX US, INC. accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Ultomiris, Vyvgart, Vyvgart Hytrulo, Zilbrysq.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Vyvgart by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART HYTRULO as an associated drug or biological on 16156 records involving 4992 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Vyvgart Hytrulo by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliris by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ultomiris by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Gamunex-C by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zilbrysq as an associated drug or biological on 5625 records involving 1862 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Zilbrysq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $60,977.12 | 40.8% | 88 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $37,475.34 | 25.1% | 43 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21,108.83 | 14.1% | 27 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17,915.86 | 12.0% | 31 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11,446.16 | 7.7% | 25 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $148.99 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.64 | 0.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.18 | 0.0% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.24 | 0.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.68 | 0.0% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.27 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.11 | 0.0% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $18.98 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.95 | 0.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.53 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118,071.00 | 46 |
| Travel and Lodging | $17,231.90 | 82 |
| Consulting Fee | $8,280.00 | 3 |
| Food and Beverage | $5,768.98 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $53,824.86 | 68 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $26,728.32 | 35 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $11,407.03 | 24 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $10,747.02 | 8 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $7,577.26 | 11 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $5,152.26 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.64 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.64 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $52.18 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 155 | exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART vyvgart |
2025 | Vyvgart | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART HYTRULO vyvgart hytrulo |
2025 | Vyvgart Hytrulo | 2024 | 45 | exact normalized | Medicare Part D |
| Zilbrysq zilbrysq |
2025 | Zilbrysq | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART HYTRULO open payments reported associated product |
CMS Open Payments — General Payments 16156 supporting records · 4992 recipient NPIs · example record 1240416058 |
Vyvgart Hytrulo · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
155 | 15 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Zilbrysq open payments reported associated product |
CMS Open Payments — General Payments 5625 supporting records · 1862 recipient NPIs · example record 1224348629 |
Zilbrysq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 334 | 95 |
| Gabapentin | Gabapentin | 304 | 91 |
| Donepezil Hcl | Donepezil Hcl | 165 | 46 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 155 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 143 | 39 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 101 | 33 |
| Pregabalin | Pregabalin | 94 | 25 |
| Levetiracetam | Levetiracetam | 77 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 51 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 16 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 45 | suppressed |
| Vyvgart Hytrulo | Efgartigimod-Hyaluronidas-Qvfc | 45 | 12 |
| Vyvgart | Efgartigimod Alfa-Fcab | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Primidone | Primidone | 36 | 16 |
| Prednisone | Prednisone | 33 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 32 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 32 | 11 |
| Ultomiris | Ravulizumab-Cwvz | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | 12 |
| Lacosamide | Lacosamide | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 18 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Zilbrysq | Zilucoplan Sodium | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Diazepam | Diazepam | 17 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Kesimpta Pen | Ofatumumab | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Soliris | Eculizumab | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Carbidopa | Carbidopa | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149,351.88 · 229 records | ARGENX US, INC. | AMVUTTRA, AUSTEDO XR, BRIUMVI, Gamunex-C, HYQVIA, KESIMPTA, NURTEC ODT, QULIPTA, Rystiggo, UBRELVY, ULTOMIRIS, UPLIZNA, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA, Zilbrysq | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ARGENX US, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error